Diagnovus to be headquartered in Nashville, Tennessee will develop diagnostic tests and provide information about rare forms of cancer, including pediatric cancers to physicians, payers, patients and families.

Diagnovus will identify, in-license, develop and market diagnostic assays that have been developed at institutions around the US.

Limestone Fund principal Joe Cook said they believe Diagnovus can focus on providing better individualized information to physicians, patients and caregivers in less frequent cancers.